Published on: February 24, 2025
Categorized as: Webinars
Results of a Phase 2 Trial of Trametinib in Advanced EHE
Scott Schuetze, MD, PhD, Rogel Cancer Center, University of Michigan
Dr. Schuetze provides an overview of the rationale for treatment of EHE with trametinib, an oral inhibitor of the MEK kinase; the trial design of 10015/SARC033; and the results of the primary and secondary study endpoints. The presentation included an update on exploratory investigation of blood-based biomarkers including hemoglobin, C-reactive protein, and connective tissue growth factor as prognostic and predictive factors in the patients with EHE who participated in the clinical trial.
